ValuEngine Upgrades SAGE Therapeutics (SAGE) to Buy

ValuEngine upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a hold rating to a buy rating in a research note published on Monday morning.

Several other brokerages also recently commented on SAGE. SunTrust Banks increased their target price on shares of SAGE Therapeutics to $178.00 and gave the company a positive rating in a report on Friday, December 8th. Cowen restated a buy rating on shares of SAGE Therapeutics in a research report on Monday, December 11th. BidaskClub upgraded shares of SAGE Therapeutics from a sell rating to a hold rating in a research report on Wednesday, March 7th. JPMorgan Chase restated an overweight rating and set a $198.00 price target on shares of SAGE Therapeutics in a research report on Friday, December 8th. Finally, Royal Bank of Canada increased their price target on shares of SAGE Therapeutics from $137.00 to $280.00 and gave the company a sell rating in a research report on Thursday, December 7th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $185.20.

How to Become a New Pot Stock Millionaire

SAGE opened at $147.40 on Monday. SAGE Therapeutics has a 1-year low of $59.57 and a 1-year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.23. During the same quarter in the previous year, the company posted ($1.50) earnings per share. research analysts expect that SAGE Therapeutics will post -8.34 earnings per share for the current year.

In other SAGE Therapeutics news, insider Stephen Kanes sold 44,000 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $177.18, for a total transaction of $7,795,920.00. Following the completion of the transaction, the insider now owns 46,348 shares in the company, valued at $8,211,938.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven M. Paul sold 58,139 shares of the stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $172.00, for a total transaction of $9,999,908.00. Following the transaction, the director now owns 632,712 shares of the company’s stock, valued at approximately $108,826,464. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the business. BlackRock Inc. boosted its position in SAGE Therapeutics by 16.4% during the fourth quarter. BlackRock Inc. now owns 3,444,171 shares of the biopharmaceutical company’s stock worth $567,290,000 after purchasing an additional 486,135 shares during the period. Palo Alto Investors LLC boosted its position in SAGE Therapeutics by 3.0% during the fourth quarter. Palo Alto Investors LLC now owns 810,806 shares of the biopharmaceutical company’s stock worth $133,548,000 after purchasing an additional 23,555 shares during the period. Franklin Resources Inc. boosted its position in SAGE Therapeutics by 10.6% during the fourth quarter. Franklin Resources Inc. now owns 524,590 shares of the biopharmaceutical company’s stock worth $86,405,000 after purchasing an additional 50,254 shares during the period. Carillon Tower Advisers Inc. bought a new position in SAGE Therapeutics during the fourth quarter worth about $74,300,000. Finally, Farallon Capital Management LLC boosted its position in SAGE Therapeutics by 64.3% during the fourth quarter. Farallon Capital Management LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $65,884,000 after purchasing an additional 156,500 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ValuEngine Upgrades SAGE Therapeutics (SAGE) to Buy” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3334715/valuengine-upgrades-sage-therapeutics-sage-to-buy.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

UBS  Given Average Recommendation of “Hold” by Analysts
UBS Given Average Recommendation of “Hold” by Analysts
MindCoin Market Cap Hits $62,382.00
MindCoin Market Cap Hits $62,382.00
Brightcove  Updates FY18 Earnings Guidance
Brightcove Updates FY18 Earnings Guidance
Middlefield Can Global  Announces Monthly Dividend of $0.05
Middlefield Can Global Announces Monthly Dividend of $0.05
Barings Participation  Announces $0.27 Quarterly Dividend
Barings Participation Announces $0.27 Quarterly Dividend
Spok Holdings, Inc.  Plans Quarterly Dividend of $0.13
Spok Holdings, Inc. Plans Quarterly Dividend of $0.13


© 2006-2018 Ticker Report. Google+.